Estrogen-only hormone therapy could lower risk of Alzheimer’s
By Maya Ellison ·
The latest medical pronouncements always feel like they are designed to do one thing: keep us paying attention, and more importantly, keep the revenue streams flowing.
The Profit Motive Behind Postmortem Plaques
The latest medical pronouncements always feel like they are designed to do one thing: keep us paying attention, and more importantly, keep the revenue streams flowing. This week’s headline—that estrogen-based menopausal hormone therapy (MHT) may lower Alzheimer's risk—is a perfect example of that mechanism at work. The reports from nypost.com and medicaldaily.com detail a study published in Neurology, analyzing brain autopsies from over 21,000 women. Researchers at Stanford Medicine found that estrogen-only MHT users had significantly lower odds of showing Alzheimer’s hallmarks—amyloid plaques and neurofibrillary tangles—at death compared to non-users. The numbers are striking: a 35% reduction in risk, according to the team.
It is easy to read "statistically significant" and feel reassured. But I am not paid to be reassured; I am paid to look at who benefits from this narrative. This study doesn't just offer data points; it offers permission. Permission for women—who are already navigating a system that treats their bodies like cash crops—to continue taking complex, often expensive, hormonal cocktails under the guise of preventative care.
When Science Needs an Advocate and Not a Skeptic
The sheer volume of conflicting findings surrounding MHT is something no one can ignore. As sciencenews.org pointed out, previous research has been messy, with some studies suggesting protection while others showed nothing or even potential harm. This study, which drew on two massive datasets, attempts to clean up the mess by focusing on "gold-standard" postmortem outcomes—the actual physical damage in the brain tissue.
The authors themselves are careful, citing Jennifer Bruno's caution that "more research needs to be done before we can make recommendations." Yet, this measured language is quickly overshadowed by the gravity of the conclusion: Estrogen may reduce the production and help clear harmful amyloids. This isn't just a scientific finding; it’s an economic lever. It shifts the conversation from lifestyle changes or structural support—like reliable public health infrastructure—to prescription adherence. The focus remains entirely on the individual, the pill bottle, and the private pathology report, rather than the systemic failures that create chronic illness in the first place.
Identifying the Agent is Not Solving the System
The core of this debate rests on identifying a specific biological agent responsible for measurable change. This brings to mind the foundational shift in medicine: the Germ Theory of Disease. That theory established that specific, identifiable pathogens—the germs—were the causal agents of infection, moving us away from vague notions of "bad humors" and toward targeted intervention.
The shared machinery here is undeniable: understanding that a specific biological agent—be it a bacterium or a hormone—can initiate measurable changes in the body's internal chemistry and structural integrity. The power of identifying the agent was revolutionary because it gave us a concrete target for public health action, moving medicine from generalized care to targeted science.
But we must be careful not to mistake this parallel mechanism for a philosophical equivalence. Just as understanding pathogens revealed localized causes of infection that required sanitation and infrastructure reform (a union job buying a house, clean water in Flint), identifying estrogen's role in plaque reduction is merely another piece of data being monetized by the same powerful interests.
The real lesson here isn't about whether MHT helps keep amyloid plaques at bay; it’s about how easily medical science can be co-opted to sell a continuous, individualized solution for problems that are fundamentally structural and societal. The focus must never drift from the fact that chronic illness—Alzheimer's, heart disease, etc.—is not simply an individual failing or a hormonal deficiency waiting for the right pill. It is the predictable cost of living in a system built on deregulation, precarious labor, and systemic neglect.
Sources
- nypost.com: Brain autopsies reveal fewer Alzheimer's signs in woman who took ...
- med.stanford.edu: Study ties estrogen-based menopausal hormone therapy to lower Alzheimer ...
- sciencenews.org: Estrogen therapy is linked to fewer signs of Alzheimer's in the brain
- sciencedaily.com: Women taking estrogen had fewer signs of Alzheimer's in their brains
- medicaldaily.com: Estrogen-Only Hormone Therapy Was Linked to Lower Alzheimer's Risk, but ...